9 results about "Hepatitis viral c" patented technology

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The present application relates to a circRNA vaccine for anti-infectious hematopoietic necrosis virus, the circRNA vaccine is a covalently closed circular structure, comprising an internal ribosome entry site, a G protein sequence of the infectious hematopoietic necrosis virus, and a Kozak sequence located between the internal ribosome entry site and the G protein sequence of the infectious hematopoietic necrosis virus;The circRNA vaccine comprises a cyclization connection sequence formed by a fish tRNA Leu I type intron self-splicing;The internal ribosome entry site is one or more of the following: coxsackievirus 3 IRES, infectious pancreatic necrosis virus IRES, encephalomyocarditis virus IRES, Ythdc2 IRES, and hepatitis C virus IRES;The amino acid sequence of the G protein of the infectious hematopoietic necrosis virus has at least 90% sequence identity with the amino acid sequence encoded by SEQ ID NO. 1.

Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3 / 4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.

Attenuated forms of virulent Zika virus and Hepatitis C virus are provided. Vaccine compositions comprising the attenuated virus and methods of eliciting a protective immune response in a subject by administering the vaccine compositions are also provided.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising HCV glycoprotein E2 from strain GT4a.ED43, and optionally, further HCV glycoproteins E2 from other strains and / or an adjuvant. The glycoprotein can be soluble glycoprotein or it can be displayed on the surface of a nanoparticle. Alternatively, it provides a composition comprising a nucleic acid encoding HCV glycoprotein E2 from strain GT4a.ED43, and, optionally, from other strains. The composition is useful as a vaccine, e.g., for prophylactic vaccination against HCV. The invention also provides a method for producing said composition as well as HCV glycoprotein E2 from strain GT2b.2b5 and a nucleic acid encoding the same.

The present application provides a composition for treating hepatitis C and a preparation method thereof. The composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition or capsule can effectively treat hepatitis C, and the preparation process is simple, safe, stable, and has rapid dissolution.